Breakthrough Clinical Trial Finds Solriamfetol Enhances Alertness and Safety for Early Morning Shift Workers Facing Shift Work Disorder
A pioneering clinical trial led by investigators at Mass General Brigham has demonstrated that solriamfetol, a wake-promoting medication currently marketed as Sunosi, significantly improves alertness and functional outcomes for individuals working early morning shifts. The study, recently published in the journal NEJM Evidence, represents a critical advancement in occupational medicine, as it is the first randomized clinical trial specifically designed to evaluate a pharmacological intervention for this particular demographic of shift workers. While much of the existing research on shift work disorder (SWD) has focused on overnight or "graveyard" shifts, this new data addresses a substantial segment of the workforce that begins labor during the biological "circadian trough"—the hours between 3:00 a.m. and 7:00 a.m. when the human body is most strongly programmed for sleep.
The Biological Conflict of the Pre-Dawn Workforce
The modern global economy relies heavily on non-traditional schedules, with approximately 20% to 25% of the workforce in industrialized nations operating outside the standard 9-to-5 window. Among these individuals, those starting work in the very early morning hours—such as logistics personnel, healthcare providers, transit operators, and manufacturing workers—constitute the largest subgroup. Despite their numbers, many of these employees do not self-identify as shift workers, often viewing their schedule as merely an "early start."
However, from a physiological perspective, these workers face a unique set of challenges. Shift work disorder is characterized by a misalignment between the internal circadian clock and the external environment. For those waking at 2:00 a.m. or 3:00 a.m. to begin a shift, the brain is attempting to function while the body is still producing melatonin and maintaining a low core temperature, both signals for deep sleep. This results in "excessive sleepiness" (ES), a condition that goes beyond mere tiredness and manifests as an irresistible urge to sleep during waking hours.
Dr. Kirsi-Marja Zitting, an investigator with the Division of Sleep and Circadian Medicine at Mass General Brigham and the study’s first author, noted that these workers face a "double burden." They must combat extreme biological pressure to sleep while on the job and then struggle to achieve restorative sleep during the daylight hours when their internal clock signals wakefulness. This chronic state of sleep debt and circadian misalignment leads to significant cognitive impairments, including slowed reaction times and reduced vigilance.
Methodology of the Solriamfetol Clinical Trial
To address the gap in treatment options for this demographic, the research team conducted a rigorous four-week, double-blind, placebo-controlled trial. The study enrolled 78 participants who met the clinical criteria for shift work disorder and were regularly scheduled for shifts starting between 3:00 a.m. and 7:00 a.m.
The participants were randomly assigned to two groups: one receiving solriamfetol and the other a placebo. Solriamfetol is a dual norepinephrine and dopamine reuptake inhibitor (NDRI). Unlike traditional stimulants like amphetamines, solriamfetol has a lower potential for abuse and a distinct pharmacokinetic profile that promotes sustained wakefulness without the "crash" often associated with shorter-acting agents.
The researchers employed several metrics to evaluate the drug’s efficacy:
- Maintenance of Wakefulness Test (MWT): Conducted in a controlled, low-stimulation laboratory environment, this test measures a person’s ability to remain awake for a set period.
- Epworth Sleepiness Scale (ESS): A subjective assessment where participants rate their likelihood of falling asleep during various daily activities.
- Clinical Global Impression of Change (CGI-C): A scale used by clinicians to assess the overall improvement or worsening of a patient’s condition relative to the start of the study.
- Functional Outcomes of Sleep Questionnaire (FOSQ-10): An evaluation of how sleepiness impacts daily tasks and quality of life.
The trial was conducted over a series of workweeks, with assessments occurring at baseline and at the conclusion of the four-week period to determine if the benefits were sustained.
Findings: Significant Gains in Alertness and Performance
The results of the trial indicated that solriamfetol provided a robust and clinically meaningful improvement in wakefulness compared to the placebo. Participants in the solriamfetol group showed a significantly greater ability to remain awake during the MWT sessions, which were timed to coincide with their actual working hours.
Beyond laboratory metrics, the subjective reports from participants and the objective assessments by clinicians told a consistent story of improvement. Those taking the medication reported that they felt more capable of managing their professional responsibilities and were less likely to experience dangerous "microsleeps"—brief, involuntary moments of sleep that can occur during monotonous tasks like driving or operating machinery.
"The improvement we saw is clinically meaningful," stated senior author Charles A. Czeisler, PhD, MD, chief of the Division of Sleep and Circadian Medicine at Mass General Brigham. "These workers were able to stay awake and alert throughout a full eight-hour shift, which has real implications for performance, safety, and quality of life."
One of the most notable findings was that solriamfetol did not appear to significantly interfere with the participants’ ability to sleep once their shift ended. This has been a major drawback of other wake-promoting agents, such as modafinil or high-dose caffeine, which can linger in the system and prevent the daytime recovery sleep that shift workers desperately need.
Occupational Safety and Economic Implications
The implications of these findings extend far beyond the clinical setting and into the realm of public safety and economic productivity. Shift work disorder is not merely a personal health issue; it is a major contributor to industrial accidents and transportation disasters.
Historical data suggests that sleep-deprived workers are 70% more likely to be involved in work-related accidents than those who are well-rested. Furthermore, the risk of a motor vehicle accident increases exponentially for shift workers during the commute home after a pre-dawn shift. By improving vigilance and reducing excessive sleepiness, solriamfetol could potentially lower the incidence of these events.
From an economic perspective, the costs associated with sleep disorders in the workforce are staggering. Reduced productivity, increased absenteeism, and higher healthcare utilization related to the comorbidities of shift work (such as cardiovascular disease and metabolic syndrome) cost the global economy billions of dollars annually. Effective management of SWD through pharmacological and behavioral interventions could mitigate some of these losses.
Comparative Analysis: Solriamfetol vs. Existing Treatments
Prior to this study, the primary pharmacological treatments for SWD were modafinil and armodafinil. While effective for many, these medications were primarily tested on night-shift workers who sleep during the day and work through the night. The early morning shift worker presents a different challenge because their "active" period overlaps with the tail end of the biological night and the start of the biological day.
Solriamfetol’s mechanism as an NDRI provides a more targeted approach to wakefulness. By inhibiting the reuptake of dopamine and norepinephrine in the brain, it enhances the signals that promote alertness. Unlike caffeine, which blocks adenosine receptors and can lead to a "rebound" effect of extreme tiredness, solriamfetol provides a more stable level of arousal.
Furthermore, the safety profile observed in this trial was consistent with previous studies of the drug in patients with narcolepsy and obstructive sleep apnea. Common side effects reported were mild, including headache, nausea, and decreased appetite, with no serious adverse events linked directly to the medication during the four-week window.
Future Directions and Research Needs
While the results are promising, the researchers at Mass General Brigham emphasized that this study is a "proof-of-concept" for this specific population. The trial’s duration was relatively short, and the participant pool consisted of generally healthy adults without significant underlying comorbidities.
The next phase of research will involve larger-scale studies to determine the long-term safety and efficacy of solriamfetol for chronic use in shift workers. Additionally, researchers are currently enrolling participants for a follow-up trial to investigate the drug’s effects on overnight shift workers, which may lead to broader regulatory approval for a wider range of circadian rhythm sleep-wake disorders.
Dr. Czeisler underscored the importance of recognizing the value of these workers. "Shift workers are essential to how our society functions—from the nurses in the emergency room to the pilots of cargo planes and the people stocking grocery shelves in the dead of night. Yet, they often pay a hidden biological cost. This study shows we can do better for them by providing evidence-based treatments that respect their biology while supporting their work."
Conclusion
The Mass General Brigham study marks a milestone in the treatment of shift work disorder, specifically for the "hidden" population of early morning workers. By demonstrating that solriamfetol can safely and effectively bridge the gap between biological sleep pressure and professional demands, the research offers a path forward for improving the health, safety, and quality of life for millions of essential personnel. As the medical community continues to explore the complexities of the human circadian clock, such targeted interventions will be vital in mitigating the risks of our 24-hour society.
